State Street Corp. Updates Passive Stake in Design Therapeutics
Ticker: DSGN · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 1807120
| Field | Detail |
|---|---|
| Company | Design Therapeutics, Inc. (DSGN) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**State Street still holds Design Therapeutics stock, a good sign for long-term investors.**
AI Summary
State Street Corporation, a major financial institution, filed an amended Schedule 13G on January 23, 2024, indicating its ownership of Design Therapeutics, Inc. common stock as of December 31, 2023. This filing is an update to their previous disclosures, confirming their continued passive investment in the pharmaceutical company. This matters to investors because it shows a large institutional investor maintains a position in Design Therapeutics, suggesting a degree of confidence in the company's long-term prospects, even if it's a passive holding.
Why It Matters
This filing confirms State Street Corporation's continued passive investment in Design Therapeutics, signaling that a major institutional player still sees value in the company's stock.
Risk Assessment
Risk Level: low — This filing is a routine update from a large institutional investor and does not indicate any immediate change in investment strategy or significant risk.
Analyst Insight
A smart investor would note State Street's continued passive holding as a sign of institutional confidence, but also recognize that a 13G filing doesn't imply active management or a change in strategy, so further research into Design Therapeutics' fundamentals is still crucial.
Key Players & Entities
- State Street Corporation (company) — the reporting person filing the SC 13G/A
- Design Therapeutics, Inc. (company) — the issuer whose common stock is being reported
- December 31, 2023 (date) — the date of the event which requires the filing
- January 23, 2024 (date) — the filing date of the SC 13G/A
- 0001807120 (number) — Central Index Key (CIK) for Design Therapeutics, Inc.
- 0000093751 (number) — Central Index Key (CIK) for State Street Corporation
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing under the Securities Exchange Act of 1934, as indicated by the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934' in the filing.
Who is the reporting person in this filing?
The reporting person is STATE STREET CORPORATION, as explicitly stated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: STATE STREET CORP' and '1. NAME OF REPORTING PERSON: STATE STREET CORPORATION'.
What is the subject company whose securities are being reported?
The subject company is Design Therapeutics, Inc., identified as 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Design Therapeutics, Inc.' and 'DESIGN THERAPEUTICS INC (NAME OF ISSUER)'.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the Common Stock of Design Therapeutics, Inc. is 25056L103, as stated under 'CUSIP NUMBER: 25056L103'.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023, as indicated by '12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding Design Therapeutics, Inc. (DSGN).